A Phase 1, Randomized, Placebo and Active Controlled, Double-Blind, Parallel, Electrocardiogram Study to Evaluate the Effect of Lumacaftor in Combination With Ivacaftor on the QT/QTc Interval in Healthy Subjects
Latest Information Update: 20 Aug 2014
Price :
$35 *
At a glance
- Drugs Ivacaftor (Primary) ; Lumacaftor (Primary) ; Moxifloxacin
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Vertex Pharmaceuticals
- 08 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Oct 2013 New trial record